<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03296098</url>
  </required_header>
  <id_info>
    <org_study_id>CCN013B</org_study_id>
    <nct_id>NCT03296098</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive</brief_title>
  <acronym>CCN013B</acronym>
  <official_title>A Multi-center, Open-label, Non-comparative Study of the Safety and Contraceptive Efficacy of Continuous Daily Oral 10 mg of Ulipristal Acetate (UPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Decisions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral&#xD;
      10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary&#xD;
      method of contraception.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study being conducted at 18 centers. The dose of 10 mg was chosen for&#xD;
      daily continuous use of ulipristal acetate (UPA). The study will enroll approximately 300&#xD;
      subjects to use the UPA for 6 months (182 days). In addition to contraceptive efficacy,&#xD;
      safety, overall acceptability of the product, and the number of bleeding/spotting days will&#xD;
      be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Awaiting FDA approval to continue&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the contraceptive efficacy at 6 months based on the calculated Pearl Index for the evaluable for pregnancy population.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (safety and tolerability) during 6 month use of UPA.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in sodium levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in potassium levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in chloride levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in bicarbonate levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fasting glucose levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood urea nitrogen levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in creatinine levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in calcium levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total bilirubin levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total alkaline phosphatase levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total alanine aminotransferase levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total aspartate transaminase levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total albumin levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in total cholesterol levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in HDL cholesterol levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in LDL cholesterol levels (safety and tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in triglycerides levels (safety and tolerability).</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in acceptability of UPA using an Acceptability Questionnaire (acceptability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in bleeding pattern using a subject diary (tolerability).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in endometrial thickness using transvaginal ultrasound.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in endometrium using endometrial biopsy results.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Contraception</condition>
  <condition>Healthy Female</condition>
  <arm_group>
    <arm_group_label>ulipristal acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal acetate</intervention_name>
    <description>Ulipristal aceteate 5 mg oral tablets to take two tablets daily.</description>
    <arm_group_label>ulipristal acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To enroll into the clinical trial, potential subjects must:&#xD;
&#xD;
          1. Be in good general overall health with no chronic medical conditions that result in&#xD;
             periodic exacerbations that require significant medical care.&#xD;
&#xD;
          2. Be women between 18 and 35 years inclusive at the enrollment visit.&#xD;
&#xD;
          3. Have regular menstrual cycles that occur every 21-35 days when not using hormonal&#xD;
             contraception.&#xD;
&#xD;
             a. If subject is postpartum or post-abortal, she must have one menstrual bleed prior&#xD;
             to enrollment.&#xD;
&#xD;
          4. Be seeking contraception, and willing to use the study drug as the only contraception&#xD;
             method during their months of study participation.&#xD;
&#xD;
          5. If using a ring, patch, pill, or implant prior to study treatment, the subject must&#xD;
             discontinue the active hormone at least 4 days, and no more than 7 days, prior to&#xD;
             study drug initiation. Note that for combined oral contraceptive users, placebo pills&#xD;
             are not counted as active hormone.&#xD;
&#xD;
          6. If using a hormonal intrauterine device (IUD) prior to study treatment, the IUD must&#xD;
             be removed prior to study drug initiation; removal and study drug initiation can occur&#xD;
             on the same day, but the subject must refrain from sexual intercourse for 7 days&#xD;
             following IUD removal.&#xD;
&#xD;
          7. If using a copper IUD prior to study treatment, the IUD must be removed prior to study&#xD;
             drug initiation; removal and study drug initiation can occur on the same day. The IUD&#xD;
             removal and study drug initiation must occur during the first 7 days of a spontaneous&#xD;
             menses.&#xD;
&#xD;
          8. If using a non-hormonal contraceptive method (e.g. condoms or withdrawal) prior to&#xD;
             study treatment, drug initiation should occur within the first 7 days of a spontaneous&#xD;
             menses.&#xD;
&#xD;
          9. If the woman has received a long-acting injectable contraceptive (e.g.&#xD;
             depomedroxyprogesterone acetate) during the 10 months prior to screening, she must&#xD;
             have resumed cyclic spontaneous menses (two menstrual bleeds) since last injection.&#xD;
&#xD;
         10. Have a negative urine pregnancy test at the enrollment visit.&#xD;
&#xD;
         11. Have an intact uterus and both ovaries.&#xD;
&#xD;
         12. In the opinion of the investigator, be willing and able to follow all study&#xD;
             requirements, including use of the study product and be willing to record requested&#xD;
             information on a daily diary.&#xD;
&#xD;
         13. Understand and sign an (Institutional Review Board) IRB approved informed consent form&#xD;
             prior to screening activities (including fasting blood draws).&#xD;
&#xD;
         14. Have a diastolic blood pressure (BP) ≤95 mm Hg and systolic BP ≤145 mm Hg after 5&#xD;
             minutes in a sitting position at the enrollment visit. Hypertensive subjects who are&#xD;
             treatment controlled and, in the judgment of the investigator, are good candidates&#xD;
             require a waiver for participation.&#xD;
&#xD;
         15. Have a body mass index (BMI) &lt; 40 kg/m2.&#xD;
&#xD;
         16. Be planning to have at least one act of heterosexual vaginal intercourse each month&#xD;
             during study participation.&#xD;
&#xD;
         17. Be willing to accept an unknown risk of pregnancy during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To enroll into the clinical trial, potential subjects must not:&#xD;
&#xD;
          1. Be women with irregular menstrual cycles defined as a variation in cycle length of&#xD;
             more than 5 days.&#xD;
&#xD;
          2. Be planning pregnancy within their months of study participation.&#xD;
&#xD;
          3. Be currently breast-feeding or within 30 days of discontinuing breast feeding, unless&#xD;
             the subject has already had a menses following discontinuation of breast feeding.&#xD;
&#xD;
          4. Have undiagnosed abnormal genital bleeding.&#xD;
&#xD;
          5. Have known hypersensitivity to the active substance UPA or any of the excipients of&#xD;
             the study treatment.&#xD;
&#xD;
          6. Have a history of endometrial hyperplasia or malignancy.&#xD;
&#xD;
          7. Have abnormal Transvaginal Ultrasound (TVUS) or safety labs done at the screening&#xD;
             visit recognized as clinically significant by the investigator (or medically qualified&#xD;
             designee).&#xD;
&#xD;
          8. Have a previous history of endometrial ablation.&#xD;
&#xD;
          9. Have a previous history of liver disease or screening liver enzyme results more than&#xD;
             three times the upper limit of normal values.&#xD;
&#xD;
         10. Have a known clinically significant Pap test abnormality, as managed by current local&#xD;
             or national guidelines, that would require treatment during study participation.&#xD;
&#xD;
         11. Have any of the following known contraindication to progestin-only oral contraceptive&#xD;
             (OC):&#xD;
&#xD;
               1. History or existing breast cancer, or other hormone sensitive neoplasia;&#xD;
&#xD;
               2. Current or history of ischemic heart disease or stroke while pregnant or taking&#xD;
                  birth control pills;&#xD;
&#xD;
               3. Systemic Lupus Erythematosus with positive or unknown antiphospholipid&#xD;
                  antibodies;&#xD;
&#xD;
               4. Benign or malignant liver tumors;&#xD;
&#xD;
               5. Severe (decompensated) cirrhosis.&#xD;
&#xD;
         12. Have known or suspected alcoholism or drug abuse.&#xD;
&#xD;
         13. Have known HIV infection.&#xD;
&#xD;
         14. Have an anticipated need for regular condom use as defined as use of at least one&#xD;
             condom per month after enrollment.&#xD;
&#xD;
         15. Have previously participated in the study.&#xD;
&#xD;
         16. Have a current need for exogenous hormones or therapeutic anticoagulants.&#xD;
&#xD;
         17. Have a current or history of deep vein thromboembolic disorder or aortic&#xD;
             thromboembolism, including stroke and myocardial infarction&#xD;
&#xD;
         18. Have a current or past medically diagnosed severe depression, which, in the opinion of&#xD;
             the investigator, could be exacerbated by use of a hormonal contraceptive, unless she&#xD;
             is stable on antidepressant medication.&#xD;
&#xD;
         19. Have concomitant use of medication thought to interact with UPA (per Summary of&#xD;
             Product Characteristics (SPCs)) such as CYP3A4 inducers (rifampin, barbiturates,&#xD;
             carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St John's&#xD;
             Wort, topiramate).&#xD;
&#xD;
         20. Have concomitant use of moderate or strong CYP3A4 inhibitors as identified by the FDA.&#xD;
             Subjects who begin use of a moderate CYP3A4 inhibitor after study enrollment require a&#xD;
             waiver to continue in the study.&#xD;
&#xD;
         21. Use any medications that can interfere with the metabolism of hormonal contraceptives,&#xD;
             antibiotics that can interfere with metabolism of hormonal contraceptives, or any&#xD;
             drugs designated by the FDA as falling in the Pregnancy and Lactation narrative&#xD;
             subsections (formerly Category D or X medications).&#xD;
&#xD;
         22. Currently participate in any other trial of an investigational medicine or device or&#xD;
             have participated in the three months before start of treatment or be planning to&#xD;
             participate in another clinical trial during this study.&#xD;
&#xD;
         23. Have a history of a bariatric surgery procedure associated with malabsorption.&#xD;
&#xD;
         24. Be planning to undergo major surgery during study participation.&#xD;
&#xD;
         25. Live outside of the catchment area of the study site.&#xD;
&#xD;
         26. Have used UPA, including Ella, within 30 days prior to enrollment and not had a menses&#xD;
             since using UPA.&#xD;
&#xD;
         27. Any site staff member with delegated study responsibilities or a family member of a&#xD;
             site staff member with delegated study responsibilities.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Essential Access</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood League of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University, School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland MacDonald Women's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School (EVMS)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Healthy Female</keyword>
  <keyword>Progestin</keyword>
  <keyword>ulipristal acetate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulipristal acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03296098
org study id: CCN013B
nct id: NCT03296098
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral
      10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary
      method of contraception.
This is an open-label study being conducted at 18 centers. The dose of 10 mg was chosen for
      daily continuous use of ulipristal acetate (UPA). The study will enroll approximately 300
      subjects to use the UPA for 6 months (182 days). In addition to contraceptive efficacy,
      safety, overall acceptability of the product, and the number of bleeding/spotting days will
      be assessed.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Other
masking: None (Open Label)
measure: Evaluate the contraceptive efficacy at 6 months based on the calculated Pearl Index for the evaluable for pregnancy population.
time frame: 6 months
measure: Incidence of treatment emergent adverse events (safety and tolerability) during 6 month use of UPA.
time frame: 6 months
measure: Changes from baseline in sodium levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in potassium levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in chloride levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in bicarbonate levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in fasting glucose levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in blood urea nitrogen levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in creatinine levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in calcium levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in total bilirubin levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in total alkaline phosphatase levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in total alanine aminotransferase levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in total aspartate transaminase levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in total albumin levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in total cholesterol levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in HDL cholesterol levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in LDL cholesterol levels (safety and tolerability).
time frame: 6 months
measure: Changes from baseline in triglycerides levels (safety and tolerability).
time frame: 10 months
measure: Changes from baseline in acceptability of UPA using an Acceptability Questionnaire (acceptability).
time frame: 6 months
measure: Changes from baseline in bleeding pattern using a subject diary (tolerability).
time frame: 6 months
measure: Changes from baseline in endometrial thickness using transvaginal ultrasound.
time frame: 6 months
measure: Changes from baseline in endometrium using endometrial biopsy results.
time frame: 6 months
arm group label: ulipristal acetate
arm group type: Experimental
description: Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
intervention type: Drug
intervention name: Ulipristal acetate
description: Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
arm group label: ulipristal acetate
criteria: 
gender: Female
gender based: Yes
minimum age: 18 Years
maximum age: 35 Years
healthy volunteers: Accepts Healthy Volunteers
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Ulipristal acetate